Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 8:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,705 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Vision Therapy Clear all
Not yet recruiting Not applicable Interventional

Visual Restoration Using Focused Ultrasound Stimulation and Immersive Virtual Reality After Stroke

NCT06875206
View directory record Official record
Conditions
Stroke, Visual Field Defect, Visual Field Defect Following Cerebrovascular Accident, Hemianopia, Quadrantanopia, Occipital Lobe Infarct, Visual Fields Hemianopsia
Interventions
Low-intensity focused ultrasound, Immersive virtual reality, Inactive Low-intensity focused ultrasound
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 24, 2026, 8:14 PM EDT
Recruiting Not applicable Interventional

Community Based Treatment for (ComBaT) Glaucoma

NCT06124521
View directory record Official record
Conditions
Glaucoma
Interventions
ComBaT Glaucoma
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
40 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Ann Arbor, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 24, 2026, 8:14 PM EDT
Active, not recruiting Not applicable Interventional

Acuity 200™ (Fluoroxyfocon A) Orthokeratology Contact Lens for Overnight Wear

NCT06009458
View directory record Official record
Conditions
Myopia
Interventions
Acuity 200™ (fluoroxyfocon A) Orthokeratology Contact Lens for Overnight Wear
Device
Lead sponsor
Acuity Polymers, Inc.
Industry
Eligibility
7 Years and older
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
9
States / cities
Mission Viejo, California • Oakland, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 24, 2026, 8:14 PM EDT
Completed Phase 3 Interventional

Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-004)

NCT00616993
View directory record Official record
Conditions
Inflammation
Interventions
Difluprednate, Placebo
Drug · Other
Lead sponsor
Sirion Therapeutics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2011 · Synced Oct 24, 2026, 8:14 PM EDT
Withdrawn Not applicable Interventional

Stop Hypernatremia, Use Metolazone, for Aggressive, Controlled, Effective Diuresis

NCT01617798
View directory record Official record
Conditions
Respiratory Failure, Volume Overload, Hypernatremia
Interventions
Supplemental metolazone diuresis, Placebo Comparator: Control-- furosemide (lasix) only
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Oct 24, 2026, 8:14 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

NCT06365853
View directory record Official record
Conditions
Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive
Interventions
Mirvetuximab Soravtansine, Lubricating Eye Drops, Prednisolone acetate ophthalmic suspension 1% eye drops, Brimonidine tartrate ophthalmic solution eye drops
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Louisville, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 24, 2026, 8:14 PM EDT
Recruiting Not applicable Interventional

Testing Mechanisms of Virtual Reality Exposure Therapy for Social Anxiety

NCT07437872
View directory record Official record
Conditions
no Interaction VRET, Scripted Interactions VRET, Fully Customized Interactions VRET
Interventions
ExpandXR
Behavioral
Lead sponsor
Palo Alto University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 24, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes

NCT04024072
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Brinzolamide 1% ophthalmic suspension, Azopt 1% Ophthalmic Suspension
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
18 Years and older
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Oct 24, 2026, 8:14 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Two-Session Couples Class to Improve Relationship Health

NCT05026372
View directory record Official record
Conditions
Stress
Interventions
Mindfulness Compassion (MC), Mindfulness Gratitude (MG), Mindfulness Value-Based Living (MV)
Behavioral
Lead sponsor
Sam Houston State University
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Huntsville, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Oct 24, 2026, 8:14 PM EDT
Not listed Not applicable Interventional

Therapy for People With Opioid Use Disorder

NCT06008769
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
12 Week Manualized Cognitive-Behavioral Therapy Intervention
Behavioral
Lead sponsor
Philadelphia College of Osteopathic Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Oct 24, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

Difluprednate Pediatric Study for the Treatment of Inflammation Post-Cataract Surgery

NCT01124045
View directory record Official record
Conditions
Cataracts, Inflammation
Interventions
Difluprednate ophthalmic emulsion, 0.05%, Prednisolone acetate ophthalmic suspension, 1.0%
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
Up to 3 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 24, 2026, 8:14 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Establishing New Treatment Approaches for Amblyopia: Perceptual Learning and Video Games

NCT05522972
View directory record Official record
Conditions
Amblyopia
Interventions
Video Game Vision Training, Perceptual Learning, Occlusion Therapy
Behavioral
Lead sponsor
Nova Southeastern University
Other
Eligibility
Not listed
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2029
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 24, 2026, 8:14 PM EDT
Completed Phase 2 Interventional

Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients

NCT06016972
View directory record Official record
Conditions
Primary Open Angle Glaucoma (POAG), Primary Open Angle Glaucoma of Both Eyes, Primary Open-Angle Glaucoma, Unspecified Eye, Ocular Hypertension (OHT)
Interventions
Experimental: QLS-111 ophthalmic solution, (0.015%), Experimental: QLS-111 ophthalmic solution, (0.03%), Experimental: QLS-111 ophthalmic solution, (0.075%), QLS-111 ophthalmic vehicle solution
Drug · Other
Lead sponsor
Qlaris Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Roswell, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Oct 24, 2026, 8:14 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Evaluation of Bepreve on the Measurement of Wheal and Flare Response From Histamine Skin Prick Testing

NCT01128556
View directory record Official record
Conditions
Histamine Responsive Allergy Patients
Interventions
Bepreve, Refresh Tears
Drug
Lead sponsor
North Texas Institute for Clinical Trials
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2010 · Synced Oct 24, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)

NCT00322556
View directory record Official record
Conditions
Agammaglobulinemia, IgG Deficiency, Common Variable Immunodeficiency
Interventions
Immunoglobulins Intravenous (Human)
Drug
Lead sponsor
CSL Behring
Industry
Eligibility
4 Years to 71 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
10
States / cities
Los Angeles, California • Centennial, Colorado • North Palm Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2012 · Synced Oct 24, 2026, 8:14 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Positive Imagery Therapy and the Incidence of Emergence Reactions With the Use of Ketamine

NCT04746079
View directory record Official record
Conditions
Procedural Sedation, Emergence Delirium
Interventions
Positive Imagery Therapy
Behavioral
Lead sponsor
Mercy Health Ohio
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 23, 2022 · Synced Oct 24, 2026, 8:14 PM EDT
Completed Not applicable Interventional

Binge Eating Anxiety and Mood

NCT04242550
View directory record Official record
Conditions
Binge-Eating Disorder, Binge Eating, Anxiety Disorders, Mood Disorders
Interventions
Executive Function- Enhanced CBT for BED (EF-BED+CBT), Cognitive Behavioral Therapy (CBT)
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Oct 24, 2026, 8:14 PM EDT
Completed Not applicable Interventional Results available

Reducing Adenoviral Patient Infected Days

NCT02472223
View directory record Official record
Conditions
Conjunctivitis, Adenoviral Conjunctivitis
Interventions
Betadine 5%, Artificial Tears
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 24, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT04285580
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Bimatoprost SR, LUMIGAN
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Dothan, Alabama • Newport Beach, California • Roswell, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 24, 2026, 8:14 PM EDT
Recruiting Not applicable Interventional

Electronic Approach to the Human Massage Therapist

NCT07040397
View directory record Official record
Conditions
Lower Back Pain
Interventions
EMMA massage therapy, Clinical massage treatment
Device · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 24, 2026, 8:14 PM EDT
Completed Phase 3 Interventional

Nepafenac Opthalmic Suspension 0.1% Compared to Acular LS for Treatment of Inflammation After Cataract Surgery

NCT00333255
View directory record Official record
Conditions
Cataract
Interventions
Nepafenac Ophthalmic Suspension, 0.1%
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
10 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Nacogdoches, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2009 · Synced Oct 24, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

Pre-operative Treatment for Patients With Untreated Pancreatic Cancer

NCT03138720
View directory record Official record
Conditions
Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer, Pancreatic Adenocarcinoma, Neoadjuvant Pancreatic Cancer
Interventions
Paclitaxel Protein Bound (Abraxane)
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 24, 2026, 8:14 PM EDT
Completed Not applicable Interventional Results available

STepped Exercise Program for Knee OsteoArthritis

NCT02653768
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Stepped Exercise Program, Arthritis Education
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Oct 24, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes

NCT04944290
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Brinzolamide/brimonidine ophthalmic suspension, Simbrinza 0.2%/1% Ophthalmic Suspension
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
18 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 24, 2026, 8:14 PM EDT